Medtronic plc (MDT) EBITDA Margin: 26.97%
Is Medtronic plc’s EBITDA margin high or low?
Medtronic plc's EBITDA margin of 26.97% is in line with its 5-year average of 26.72%, around the middle of its 5-year range (24.98%–27.85%).
As of Wednesday, June 17, 2026. 0.95% below its 12-month average of 27.23%.
MDT EBITDA Margin Chart
MDT Average EBITDA Margin Chart
MDT Current vs Average EBITDA Margin Chart
MDT EBITDA Margin Metrics
EBITDA MARGIN
26.97%
EBITDA MARGIN AVG TTM
27.23%
EBITDA MARGIN AVG 3Y
26.91%
EBITDA MARGIN AVG 5Y
26.72%
EBITDA MARGIN AVG 10Y
28.00%
EBITDA MARGIN AVG 15Y
28.79%
EBITDA MARGIN AVG 20Y
29.42%
CURRENT VS TTM AVG
-0.95%
CURRENT VS 3Y AVG
+0.20%
CURRENT VS 5Y AVG
+0.92%
CURRENT VS 10Y AVG
-3.68%
CURRENT VS 15Y AVG
-6.32%
CURRENT VS 20Y AVG
-8.32%
MDT Competitors' EBITDA Margin
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Medtronic plc (MDT) | $103.29B | 26.97% | 27.23% | 26.91% | 26.72% |
| Bristol-Myers Squibb Company (BMY)vs › | $114.19B | 30.18% | 18.37% | 30.35% | 29.39% |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $115.02B | 40.28% | 22.34% | 35.25% | 38.74% |
| HCA Healthcare, Inc. (HCA)vs › | $88.05B | 20.64% | 20.16% | 20.49% | 20.85% |
| Stryker Corporation (SYK)vs › | $119.06B | 25.14% | 23.50% | 23.36% | 22.67% |
| Elevance Health Inc. (ELV)vs › | $85.70B | 4.85% | 5.39% | 5.84% | 6.22% |
| CVS Health Corporation (CVS)vs › | $127.73B | 2.45% | 3.06% | 3.76% | 4.57% |
| Danaher Corporation (DHR)vs › | $128.06B | 28.27% | 29.38% | 31.44% | 31.51% |
| Cigna Corporation (CI)vs › | $76.25B | 4.22% | 4.42% | 5.04% | 5.39% |
| Boston Scientific Corporation (BSX)vs › | $69.74B | 25.42% | 24.47% | 23.70% | 21.87% |
Margin Comparison
Gross Margin
65.0%
EBITDA Margin
27.0%
Operating Margin
17.8%
Net Margin
13.2%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
- Removes effects of depreciation policies (D&A)
- Capital structure neutral (ignores interest)
- Tax neutral (ignores tax differences)
- Good proxy for operating cash generation
Medtronic plc EBITDA Margin Formula & Definition
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Medtronic plc EBITDA Margin FAQ
- What is the EBITDA margin for Medtronic plc (MDT)?
- The EBITDA margin for MDT stock is 26.97%.
- Is Medtronic plc's EBITDA margin high or low?
- Medtronic plc's EBITDA margin of 26.97% is in line with its 5-year average of 26.72%, around the middle of its 5-year range (24.98%–27.85%).
- What is the TTM average EBITDA margin for Medtronic plc (MDT)?
- The TTM average EBITDA margin for MDT stock is 27.23%.
- What is the 3Y average EBITDA margin for Medtronic plc (MDT)?
- The 3Y average EBITDA margin for MDT stock is 26.91%.
- What is the 5Y average EBITDA margin for Medtronic plc (MDT)?
- The 5Y average EBITDA margin for MDT stock is 26.72%.
- What is the 10Y average EBITDA margin for Medtronic plc (MDT)?
- The 10Y average EBITDA margin for MDT stock is 28.00%.
- What is the 15Y average EBITDA margin for Medtronic plc (MDT)?
- The 15Y average EBITDA margin for MDT stock is 28.79%.
- What is the 20Y average EBITDA margin for Medtronic plc (MDT)?
- The 20Y average EBITDA margin for MDT stock is 29.42%.
Medtronic plc EBITDA Margin History
| DATE | EBITDA MARGIN |
|---|---|
| 2026-04-24 | 26.97% |
| 2025-04-30 | 27.49% |
| 2024-04-30 | 25.35% |
| 2023-04-30 | 27.85% |
| 2022-04-30 | 27.70% |
| 2021-04-30 | 24.98% |
| 2020-04-30 | 27.01% |
| 2019-04-30 | 30.43% |
| 2018-04-30 | 31.60% |
| 2017-04-30 | 28.99% |
| 2016-04-30 | 29.63% |
| 2015-04-30 | 26.94% |
| 2014-04-30 | 29.01% |
| 2013-04-30 | 32.90% |
| 2012-04-30 | 32.92% |
| 2011-04-30 | 30.87% |
| 2010-04-30 | 32.36% |
| 2009-04-30 | 24.04% |
| 2008-04-30 | 27.95% |
| 2007-04-30 | 35.14% |
| 2006-04-30 | 37.63% |
| 2005-04-30 | 38.86% |
| 2004-04-30 | 39.88% |
| 2003-04-30 | 39.94% |
| 2002-04-30 | 38.67% |
| 2001-04-30 | 39.19% |
| 2000-04-30 | 38.44% |
| 1999-04-30 | 38.21% |
| 1998-04-30 | 48.30% |
| 1997-04-30 | 42.87% |
Related Metrics
About Medtronic plc
Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Geoffrey Straub Martha